Publications
Publications
Show Results For
- All HBS Web
(119,459)
- Faculty Publications (197)
Patents
→
- Article
Policy Implications of Weak Patent Rights
By: James J. Anton, Hillary Greene and Dennis Yao
Patents vary substantially in the degree of protection provided against unauthorized imitation. In this chapter we explore a range of work addressing the economic and policy implications of "weak" patents—patents that have a significant probability of being overturned... View Details
- 2006
- Other Unpublished Work
The RAD-Patent-LRD Mapping Project
By: William R. Kerr and Shihe Fu
Keywords: Patents
- December 2005 (Revised August 2006)
- Case
Amgen Inc.'s Epogen--Commercializing the First Biotech Blockbuster Drug
By: Felix Oberholzer-Gee and Dennis A. Yao
Amgen Inc.'s Epogen was the first biotech blockbuster drug. Epogen helped prevent anemia, a condition that leads to severe fatigue, increased risk of cardiovascular disease, and even death. At the time, the market for Epogen, which included dialysis patients and... View Details
- December 2005 (Revised February 2019)
- Case
Brighter Smiles for the Masses--Colgate vs. P&G
By: Felix Oberholzer-Gee, Dennis Yao and Filipa Azevedo Jorge
In 2000, Procter & Gamble Co. introduced Crest Whitestrips, a new, revolutionary product that allowed consumers to whiten their teeth at home. With Whitestrips, P&G created an entire new category in oral care, worth $460 million in 2002. Whitestrips sent P&G's main... View Details
- Article
Discussion of "Ivory Tower and Industrial Innovation: University-Industry Technology Transfer Before and After the Bayh-Dole Act in the United States" by David C. Mowery, Richard R. Nelson, Bhaven N. Sampat, and Arvids A. Ziedonis
By: Josh Lerner
- Comment
Patent Citations and the Geography of Knowledge Spillovers: A Reassessment: Comment
By: Rebecca M. Henderson, Adam Jaffe and Manuel Trajtenberg
- October 2004 (Revised March 2005)
- Case
Langer Lab, The: Commercializing Science
By: H. Kent Bowen, Alex Kazaks, Ayr Muir-Harmony and Bryce LaPierre
Professor Robert Langer's laboratory at MIT is the source of an unusually large number of published papers, patents, and technology licenses to start-up and established companies in the biomedical industry. Explores Langer's leadership and other factors that create a... View Details
- May 2004
- Background Note
56K Modem Battle
By: David B. Yoffie and Deborah Freier
Examines the battle to set the standard for the 56K modem. Set in 1996, this case looks at how computers accessed the Internet via a telephone line, or dial-up connection, and a hardware modem. In 1995, there were 18.6 million total modem unit shipments, with market... View Details
- May 2004 (Revised April 2005)
- Background Note
Intellectual Property and Strategy
By: David B. Yoffie and Deborah Freier
Explores the role of intellectual property in firms' strategies. Explains the legal and strategic differences between patents, copyrights, trademarks, and trade secrets and explores the multiple ways firms use these different legal protections to gain competitive... View Details
- May 2004
- Article
Was Electricity a General Purpose Technology: Evidence from Historical Patent Citations
By: Tom Nicholas and Petra Moser
- Article
Little Patents and Big Secrets: Managing Intellectual Property
By: James J. Anton and Dennis A. Yao
Exploitation of an innovation commonly requires some disclosure of enabling knowledge (e.g., to obtain a patent or induce complementary investment). When property rights offer only limited protection, the value of the disclosure is offset by the increased threat of... View Details
Keywords: Patents; Management; Innovation and Invention; Knowledge; Rights; Value; Information; Corporate Disclosure
- Article
Why Schumpeter Was Right: Innovation, Market Power and Creative Destruction in 1920s America
By: Tom Nicholas
Are firms with strong market positions powerful engines of technological progress? Joseph Schumpeter thought so, but his hypothesis has proved difficult to verify empirically. This article highlights Schumpeterian market-power and creative-destruction effects in a... View Details
- summer 2003
- Article
Patents, Invalidity, and the Strategic Transmission of Enabling Information
By: James J. Anton and Dennis A. Yao
The patent system encourages innovation and knowledge disclosure by providing exclusivity to inventors. Exclusivity is limited, however, because a substantial fraction of patents have some probability of being ruled invalid when challenged in court. The possibility of... View Details
- June 2003 (Revised May 2006)
- Case
Cipla
By: Rohit Deshpande and Laura Winig
The head of Cipla, a $325-million-dollar Indian pharmaceutical company and seller of low-cost AIDS drugs to South Africa, must decide what to do about Cipla's future. With India poised to enforce international patents in only two years, much of Cipla's product line... View Details
- May 2003
- Teaching Note
Performance Indicator (TN)
By: Kenneth S. Corts and Jan W. Rivkin
Teaching Note for (9-702-480). View Details
- October 2002 (Revised October 2003)
- Case
Aspen Aerogels
By: William A. Sahlman and Taslim Pirmohamed
Describes a newly formed manufacturer of insulation materials. The company has developed and patented a new insulation material that can be used in a wide range of markets. Capital must be raised to finance building a manufacturing facility and fund early market... View Details
- June 2002 (Revised November 2005)
- Case
Life, Death, and Property Rights: The Pharmaceutical Industry Faces AIDS in Africa
By: Debora L. Spar
In the final years of the 20th century, the world was hit by a plague of epidemic proportions--AIDS, a life-threatening disease that remained stubbornly immune to any cure or vaccine. In the developed nations of the West, AIDS was slowly brought under control through a... View Details